protriptyline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antidepressants, dibenzo[a,d]cycloheptane or cyclopheptene derivatives 2320 438-60-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • protriptyline
  • protryptyline
  • triptil
  • protriptyline hydrochloride
  • protriptyline HCl
Tricyclic antidepressant similar in action and side effects to IMIPRAMINE. It may produce excitation.
  • Molecular weight: 263.38
  • Formula: C19H21N
  • CLOGP: 4.72
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 12.03
  • ALOGS: -6.06
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.25 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 85 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
fu (Fraction unbound in plasma) 0.14 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.106 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.501 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 40.087 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 35.727 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 7.500 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 24.920 % High 1
herg hERG pIC50 5.186 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 24.660 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 17.418 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 24.070 % High 1
kinase-safety-class ACVR2A,ACVR2B,AKT1,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK 52
kinase-selectivity-class AXL,BRAF,GRK2,PDK4,STK33,TTK 6
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.813 High 1
mh-clint Mouse hepatocyte intrinsic clearance 169.824 High 1
mppb Mouse plasma protein binding (% unbound) 13.150 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.047 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 23.940 % High 1
rh-clint Rat hepatocyte intrinsic clearance 390.841 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 48.220 % High 1
rppb Rat plasma protein binding (% unbound) 22.500 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 961.612 uM High 1

Approvals:

DateAgencyCompanyOrphan
Sept. 27, 1967 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AA11 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Non-selective monoamine reuptake inhibitors
MeSH PA D000928 Antidepressive Agents
MeSH PA D000929 Antidepressive Agents, Tricyclic
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018663 Adrenergic Agents
MeSH PA D018759 Adrenergic Uptake Inhibitors
MeSH PA D049990 Membrane Transport Modulators
FDA EPC N0000175752 Tricyclic Antidepressant
CHEBI has role CHEBI:35469 antidepressant

Related Drugs by ATC class:

N06AA Non-selective monoamine reuptake inhibitors 20 drugs
amineptineamitriptylineamoxapinebutriptylineclomipraminedesipraminedibenzepindimetacrinedosulepindoxepinimipramineimipramine oxide show all 20 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Depressive disorder indication 35489007
Cataplexy off-label use 46263000
Ocular hypertension contraindication 4210003 DOID:9282
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Bipolar disorder contraindication 13746004 DOID:3312
Electroconvulsive therapy contraindication 23835007
Glaucoma contraindication 23986001 DOID:1686
Hyperthyroidism contraindication 34486009 DOID:7998
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Dementia contraindication 52448006
Schizophrenia contraindication 58214004 DOID:5419
Chronic idiopathic constipation contraindication 82934008
Hiatal hernia contraindication 84089009 DOID:12642
Seizure disorder contraindication 128613002
Asthma contraindication 195967001 DOID:2841
Gastroesophageal reflux disease contraindication 235595009 DOID:8534
Disease of liver contraindication 235856003 DOID:409
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Surgical procedure contraindication 387713003
Angle-closure glaucoma contraindication 392291006 DOID:13550
Myocardial infarction in recovery phase contraindication 418044006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.04 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 7.34 WOMBAT-PK CHEMBL
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Ki 8.39 WOMBAT-PK CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.93 WOMBAT-PK
5-hydroxytryptamine receptor 2C GPCR Ki 6.50 WOMBAT-PK
Histamine H1 receptor GPCR Ki 7.22 WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR Ki 7.70 WOMBAT-PK
Muscarinic acetylcholine receptor M2 GPCR Ki 6.90 WOMBAT-PK
Muscarinic acetylcholine receptor M3 GPCR Ki 7 WOMBAT-PK
Muscarinic acetylcholine receptor M4 GPCR Ki 6.94 WOMBAT-PK
Muscarinic acetylcholine receptor M5 GPCR Ki 6.86 WOMBAT-PK
Sodium-dependent dopamine transporter Transporter Ki 5.68 PDSP
Adenosine receptor A3 GPCR IC50 8.96 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 7.20 WOMBAT-PK
Voltage-dependent N-type calcium channel subunit alpha-1B Ion channel IC50 4.85 CHEMBL
5-hydroxytryptamine receptor 2B GPCR Ki 7 WOMBAT-PK

External reference:

IDSource
4019918 VUID
N0000148003 NUI
D00484 KEGG_DRUG
1225-55-4 SECONDARY_CAS_RN
4017927 VANDF
4019918 VANDF
C0033743 UMLSCUI
CHEBI:8597 CHEBI
CHEMBL668 ChEMBL_ID
DB00344 DRUGBANK_ID
CHEMBL1200332 ChEMBL_ID
D011530 MESH_DESCRIPTOR_UI
4976 PUBCHEM_CID
7285 IUPHAR_LIGAND_ID
1663 INN_ID
4NDU154T12 UNII
203199 RXNORM
2338 MMSL
5381 MMSL
d00875 MMSL
001504 NDDF
004603 NDDF
372760009 SNOMEDCT_US
46950002 SNOMEDCT_US
49299006 SNOMEDCT_US
4NDU154T12 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Protriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-0210 TABLET 5 mg ORAL ANDA 17 sections
Protriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-0211 TABLET 10 mg ORAL ANDA 17 sections
Protriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42794-004 TABLET, FILM COATED 5 mg ORAL ANDA 15 sections
Protriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42794-007 TABLET, FILM COATED 10 mg ORAL ANDA 15 sections
Protriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42806-096 TABLET, FILM COATED 5 mg ORAL ANDA 19 sections
Protriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42806-097 TABLET, FILM COATED 10 mg ORAL ANDA 19 sections